254 related articles for article (PubMed ID: 35008546)
1. Cysteinyl Leukotriene Pathway and Cancer.
Tsai MJ; Chang WA; Chuang CH; Wu KL; Cheng CH; Sheu CC; Hsu YL; Hung JY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008546
[TBL] [Abstract][Full Text] [Related]
2. Leukotriene D4 accelerates antigen-mediated mast cell responses via the cysteinyl leukotriene 1 receptor.
Fujisawa S; Nagata Y; Suzuki R
Cell Immunol; 2022 Dec; 382():104632. PubMed ID: 36274438
[TBL] [Abstract][Full Text] [Related]
3. Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT₂) agonist, N-methyl-leukotriene C₄, in calcium reporter and β arrestin assays.
Yan D; Stocco R; Sawyer N; Nesheim ME; Abramovitz M; Funk CD
Mol Pharmacol; 2011 Feb; 79(2):270-8. PubMed ID: 21078884
[TBL] [Abstract][Full Text] [Related]
4. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics.
Singh RK; Gupta S; Dastidar S; Ray A
Pharmacology; 2010; 85(6):336-49. PubMed ID: 20516735
[TBL] [Abstract][Full Text] [Related]
5. Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome.
Gautier-Veyret E; Bäck M; Arnaud C; Belaïdi E; Tamisier R; Lévy P; Arnol N; Perrin M; Pépin JL; Stanke-Labesque F
Pharmacol Res; 2018 Aug; 134():311-319. PubMed ID: 29920371
[TBL] [Abstract][Full Text] [Related]
6. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema.
Ikeda G; Miyahara N; Koga H; Fuchimoto Y; Waseda K; Kurimoto E; Taniguchi A; Tanimoto Y; Kataoka M; Tanimoto M; Kanehiro A
Am J Respir Cell Mol Biol; 2014 Jan; 50(1):18-29. PubMed ID: 23937413
[TBL] [Abstract][Full Text] [Related]
7. Cysteinyl leukotriene receptor 1 regulates glucose-stimulated insulin secretion (GSIS).
Guo R; Jiang J; Jing Z; Chen Y; Shi Z; Deng B
Cell Signal; 2018 Jun; 46():129-134. PubMed ID: 29412178
[TBL] [Abstract][Full Text] [Related]
8. Leukotriene D
Al-Azzam N; Elsalem L
Life Sci; 2020 Nov; 260():118452. PubMed ID: 32956660
[TBL] [Abstract][Full Text] [Related]
9. Blockade of Platelet CysLT1R Receptor with Zafirlukast Counteracts Platelet Protumoral Action and Prevents Breast Cancer Metastasis to Bone and Lung.
Saier L; Ribeiro J; Daunizeau T; Houssin A; Ichim G; Barette C; Bouazza L; Peyruchaud O
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293074
[TBL] [Abstract][Full Text] [Related]
10. Role of Cysteinyl Leukotrienes in Allergic Rhinitis.
Shirasaki H; Himi T
Adv Otorhinolaryngol; 2016; 77():40-5. PubMed ID: 27115997
[TBL] [Abstract][Full Text] [Related]
11. Human T(H)2 cells respond to cysteinyl leukotrienes through selective expression of cysteinyl leukotriene receptor 1.
Parmentier CN; Fuerst E; McDonald J; Bowen H; Lee TH; Pease JE; Woszczek G; Cousins DJ
J Allergy Clin Immunol; 2012 Apr; 129(4):1136-42. PubMed ID: 22391114
[TBL] [Abstract][Full Text] [Related]
12. Montelukast, a cysteinyl leukotriene receptor antagonist, inhibits the growth of chronic myeloid leukemia cells through apoptosis.
Zovko A; Yektaei-Karin E; Salamon D; Nilsson A; Wallvik J; Stenke L
Oncol Rep; 2018 Aug; 40(2):902-908. PubMed ID: 29845257
[TBL] [Abstract][Full Text] [Related]
13. Functional expression of cysteinyl leukotriene receptors on human platelets.
Hasegawa S; Ichiyama T; Hashimoto K; Suzuki Y; Hirano R; Fukano R; Furukawa S
Platelets; 2010; 21(4):253-9. PubMed ID: 20433311
[TBL] [Abstract][Full Text] [Related]
14. Functional characterisation of receptors for cysteinyl leukotrienes in smooth muscle.
Jonsson EW
Acta Physiol Scand Suppl; 1998 Mar; 641():1-55. PubMed ID: 9597121
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the human cysteinyl leukotriene 2 receptor.
Heise CE; O'Dowd BF; Figueroa DJ; Sawyer N; Nguyen T; Im DS; Stocco R; Bellefeuille JN; Abramovitz M; Cheng R; Williams DL; Zeng Z; Liu Q; Ma L; Clements MK; Coulombe N; Liu Y; Austin CP; George SR; O'Neill GP; Metters KM; Lynch KR; Evans JF
J Biol Chem; 2000 Sep; 275(39):30531-6. PubMed ID: 10851239
[TBL] [Abstract][Full Text] [Related]
16. Cysteinyl leukotrienes C4 and D4 downregulate human mast cell expression of toll-like receptors 1 through 7.
Karpov V; Ilarraza R; Catalli A; Kulka M
J Biol Regul Homeost Agents; 2018; 32(2):233-239. PubMed ID: 29685001
[TBL] [Abstract][Full Text] [Related]
17. Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules.
Neves JS; Radke AL; Weller PF
J Allergy Clin Immunol; 2010 Feb; 125(2):477-82. PubMed ID: 20159258
[TBL] [Abstract][Full Text] [Related]
18. Endogenous production of leukotriene D4 mediates autocrine survival and proliferation via CysLT1 receptor signalling in intestinal epithelial cells.
Paruchuri S; Mezhybovska M; Juhas M; Sjölander A
Oncogene; 2006 Oct; 25(50):6660-5. PubMed ID: 16715140
[TBL] [Abstract][Full Text] [Related]
19. A novel therapeutic potential of cysteinyl leukotrienes and their receptors modulation in the neurological complications associated with Alzheimer's disease.
Rahman SO; Singh RK; Hussain S; Akhtar M; Najmi AK
Eur J Pharmacol; 2019 Jan; 842():208-220. PubMed ID: 30389631
[TBL] [Abstract][Full Text] [Related]
20. Comparison study between the mechanisms of allergic asthma amelioration by a cysteinyl-leukotriene type 1 receptor antagonist montelukast and methylprednisolone.
Murai A; Abe M; Hayashi Y; Sakata N; Katsuragi T; Tanaka K
J Pharmacol Exp Ther; 2005 Feb; 312(2):432-40. PubMed ID: 15470084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
